- Resource Centers
The FDA approved GlaxoSmithKline's influenza vaccine, Fluarix, indicated for adults 18 years and older, following a phase 3 clinical trial. The randomized, double-blind, placebo- controlled study of approximately 1000 US adults showed Fluarix to be safe and immunogenic. Fluarix will be available to health care practitioners in prefilled Tip-Lok syringes in time for this year's flu season. John Treanor, MD, of the University of Rochester Medical Center, commented, "The introduction of Fluarix is a vital step in the effort to improve vaccination rates in the United States and protect against this highly communicable infection that threatens young and old alike." GlaxoSmithKline's Chief Executive Officer Jean-Pierre Garnier remarked, "The shortage of the flu vaccine last year was a reminder of the importance of vaccines in health care."
Ms. Farley is a freelance medical writer based in Wakefield, RI.